Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma

Neuro-Oncology

Volumn 16, Issue 11, 2014, Pages 1478-1483

  Chen, Li ^a,b   Voronovich, Zoya ^c   Clark, Kenneth ^c   Hands, Isaac ^a   Mannas, Jonathan ^d   Walsh, Meggen ^d   Nikiforova, Marina N ^c   Durbin, Eric B ^a,b   Weiss, Heidi ^a,b   Horbinski, Craig ^d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Glioma; IDH1; IDH2

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER INFILTRATION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROBABILITY; STATISTICAL MODEL; BRAIN NEOPLASMS; DNA MUTATIONAL ANALYSIS; FOLLOW UP; GENETICS; MIDDLE AGED; MUTATION; PROGNOSIS; VALIDATION STUDY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MODELS, STATISTICAL; MUTATION; NEOPLASM GRADING; PROGNOSIS; VALIDATION STUDIES AS TOPIC; YOUNG ADULT;

EID: 84925946260     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou097     Document Type: Article

References (16)

1. Horbinski C. What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol. 2013;125(5):621-636.
2. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744.
3. Horbinski C, Kofler J, Yeaney G, et al. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathol. 2011;21(5):564-74.
4. Camelo-Piragua S, Jansen M, Ganguly A, et al. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol. 2011;70(2):110-115.
5. Camelo-Piragua S, Jansen M, Ganguly A, et al. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol. 2010;119(4):509-511.
6. Capper D, Reuss D, Schittenhelm J, et al. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol. 2011;121(2):241-252.
7. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2009;20(1):245-254.
8. Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009;118(5):599-601.
9. Cline MS, Craft B, Swatloski T, et al. Exploring TCGA pan-cancer data at the UCSC Cancer Genomics Browser. Sci Rep. 2013;3:2652.
10. Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 2013;126(3):443-51.
11. Mayers JR, Vander Heiden MG. BCAT1 defines gliomas by IDH status. Nat Med. 2013;19(7):816-817.
12. Elkhaled A, Jalbert LE, Phillips JJ, et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med. 2012;4(116):116ra115.
13. Chaumeil MM, Larson PE, Yoshihara HA, et al. Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nat Commun. 2013;4:2429.
14. Choi C, Ganji SK, DeBerardinis RJ, et al. 2-Hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012;18(4):624-629.
15. Andronesi OC, Kim GS, Gerstner E, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 2012;4(116):116ra114.
16. Pope WB, Prins RM, Albert Thomas M, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol. 2012;107(1):197-205.